Serotonin syndrome due to association of venlafaxine, maprotiline and reboxetine.
Bertolín-Guillén
José-Manuel
JM
Climent-Díaz
Benjamín
B
Navarré-Gimeno
Arancha
A
D003511:Cyclohexanols / Q000009:adverse effects* / Q000627:therapeutic use; D003866:Depressive Disorder / Q000188:drug therapy*; D004632:Emergency Medical Services; D006801:Humans; D008297:Male; D008376:Maprotiline / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D009025:Morpholines / Q000009:adverse effects* / Q000627:therapeutic use; D000077593:Reboxetine; D020230:Serotonin Syndrome / Q000139:chemically induced* / Q000534:rehabilitation; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000069470:Venlafaxine Hydrochloride
D003511:Cyclohexanols; D008376:Maprotiline; D009025:Morpholines; D000077593:Reboxetine; D017367:Selective Serotonin Reuptake Inhibitors; D000069470:Venlafaxine Hydrochloride